Management of the antiphospholipid syndrome

Abstract

Antiphospholipid syndrome (APS) is characterized by recurrent venous or arterial thromboses, fetal losses and thrombocytopenia in the presence of antiphospholipid antibodies, namely lupus anticoagulant, anticardiolipin antibodies or antibodies directed to various proteins, mainly β 2 glycoprotein I, or all three. There is consensus in treating patients with APS and first venous thrombosis with oral anticoagulation to a target international normalized ratio (INR) of 2.0–3.0. A recent systematic review recommended a target INR of >3.0 in those patients with APS and arterial thrombosis. The approach in women with obstetric manifestations of APS is based on the use of aspirin plus heparin. The best treatment for patients with the catastrophic variant of the APS is a combination of anticoagulation, corticosteroids, and plasma exchange or intravenous immunoglobulins.

CMR detects extensive intracavitary thrombi as solitary clinical presentation of Antiphospholipid Syndrome: A case report

“…Of note, at least one specific antibody, either Lupus coagulant, Anti‐Cardiolipin antibodies or Anti‐β 2 Glycoprotein I, has to be positive in two separate measurements within 3 months apart to confirm diagnosis of APS. Treatment in most cases consists of life‐long anticoagulation 10 …”

Treatment of the antiphospholipid syndrome

“…The so-called “seronegative” APS, patients whose aPL antibodies turn negative, and aPL-positive patients who do not formally satisfy the criteria for APS represent unusual situations [ 53 ] which pose particularly challenging treatment problems [ 54 ].…”

Rozlane Krwawienie Pęcherzykowe Jako Jedyna Manifestacja ZespołU Antyfosfolipidowego

“…Ustalenie ostatecznego rozpoznania APS jest istotne dla leczenia, które generalnie polega (u chorych objawowych) na stosowaniu preparatów przeciwzakrzepowych [18]. Szczególną grupą chorych są ci, u których występują objawy DAH.…”